The Cooper Companies, Inc. (NASDAQ:COO) Stock Position Raised by Tortoise Investment Management LLC

Tortoise Investment Management LLC lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 77.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 790 shares of the medical device company’s stock after buying an additional 344 shares during the period. Tortoise Investment Management LLC’s holdings in Cooper Companies were worth $73,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Ashton Thomas Securities LLC bought a new position in Cooper Companies in the 3rd quarter worth about $25,000. Byrne Asset Management LLC bought a new position in Cooper Companies in the 4th quarter worth about $33,000. OFI Invest Asset Management bought a new position in Cooper Companies in the 4th quarter worth about $34,000. Covestor Ltd grew its position in Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after purchasing an additional 200 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its position in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Down 6.0 %

COO stock opened at $79.89 on Tuesday. The Cooper Companies, Inc. has a 12 month low of $79.74 and a 12 month high of $112.38. The firm has a market cap of $15.94 billion, a PE ratio of 40.97, a P/E/G ratio of 2.25 and a beta of 1.02. The firm has a 50 day simple moving average of $92.14 and a 200 day simple moving average of $99.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Robert W. Baird decreased their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday. Wells Fargo & Company upped their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Citigroup reduced their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research note on Friday. Finally, Stifel Nicolaus reduced their price target on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.